IL37 and myeloid sarcoma: These findings were subsequently confirmed in another independent study that demonstrated that serum levels of IL37 were higher in patients with MS and correlated with disease activity as well as with the levels of IL33 and soluble vascular endothelial growth factor (VEGF) receptor 2 [34].